GILD

Gilead Sciences
D

GILD

108.190
USD
-0.62
(-0.57%)
مغلق
حجم التداول
166,258
الربح لكل سهم
8
العائد الربحي
2.87
P/E
23
حجم السوق
134,580,691,601
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 8 أشهر
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة
ABBV
ABBV
-2.160
(-1.13%)
189.260 USD
AMGN
AMGN
-3.67
(-1.23%)
294.70 USD
BIIB
BIIB
-3.731
(-2.90%)
124.999 USD
INCY
INCY
-1.120
(-1.62%)
67.850 USD
MRK
MRK
-1.540
(-1.89%)
79.970 USD
NVS
NVS
-0.320
(-0.28%)
114.200 USD
PFE
PFE
-0.135
(-0.55%)
24.460 USD
REGN
REGN
-7.51
(-1.37%)
542.46 USD
SNY
SNY
-0.330
(-0.68%)
48.310 USD
المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).